Saturday 17 October 2026 Export OSRH’s income statement to Excel — free account

OSR Health, Inc.

OSR Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, down 17.7% from fiscal 2024. In the quarter to June 2026, revenue fell 72.2%, EPS fell 200.0%, free cash flow fell 398.8% and total debt rose 28.2%, each against the same quarter a year earlier.

0.22 0.02 +10.00%

Follow OSRH

Alert me

Market cap: $4.1M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: −0.59
Beneish M: −4.91
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 40.96%

Capital & Financial Ratios $m

Market Cap 4.09

Revenue 1.81

Net Income (14.91)

Free Cash Flow (7.20)

Net Debt 3.93

Current Ratio 0.18

Debt/Equity 0.04

P/E ratio 0.00

Fwd P/E —

P/S ratio 4.00

P/B ratio 0.06

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	0	0	2	1
Receivables	—	1	0	0
Inventory	—	1	0	1
Other	—	0	1	1
	0	2	3	3

	2023	2024	2025	Q'26
Payables	1	1	8	8
ST’ Debt	0	2	4	5
Other	—	0	4	1
	2	3	17	16

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	911.46%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	1	1	1	0	3

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(2)	—	—	—
’25	0	0	(3)	(1)	(4)
’24	0	0	(1)	0	(2)
’23	0	0	0	0	(1)
’22	0	0	0	0	0
’21	—	—	—	0	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(2)	—	—	—
’25	0	0	(3)	(2)	(5)
’24	0	0	(1)	0	(2)
’23	0	0	0	0	(1)
’22	0	0	0	0	0
’21	—	—	—	0	0

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.09)	(0.02)	—	—	—
’25	(1.04)	0.02	(0.10)	(0.16)	(1.39)
’24	(0.60)	(0.41)	(1.56)	(2.23)	(4.79)
’23	0.02	0.03	0.01	(0.01)	0.05
’22	0.00	0.00	(0.01)	(0.01)	(0.02)
’21	—	—	—	—	0.00

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	10.07	10.50	0.45	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	11.16	13.40	12.54
People
People	Employees	—	—	—	—	—	—	—	—	21	4
	Revenue/emp, $m	—	—	—	—	—	—	—	—	0.17	0.73
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	4	3
	Gross margin, %	—	—	—	—	—	—	—	—	22.98	20.40
	EBT	—	—	—	—	0	0	0	1	(12)	(29)
	EBT margin, %	—	—	—	—	0.00	0.00	0.00	0.00	(336.88)	(994.16)
	Net income	—	—	—	—	0	0	0	0	(10)	(27)
	Depreciation	—	—	—	—	—	—	—	—	10	9
Per share, $
Per share, $	Revenue	—	—	—	—	0.00	0.00	0.00	0.00	1.64	0.15
	Earnings	—	—	—	—	0.00	0.00	(0.02)	0.06	(4.79)	(1.39)
	Cash flow	—	—	—	—	0.00	0.00	0.00	(0.11)	(0.86)	(0.22)
	Capex	—	—	—	—	0.00	0.00	0.00	0.00	0.00	(0.03)
	Free cash flow	—	—	—	—	0.00	0.00	0.00	(0.11)	(0.86)	(0.25)
	Book value	—	—	—	—	0.00	0.00	(0.02)	(0.51)	66.45	6.51
	Shares, m	—	—	—	—	8	2	2	8	2	20
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	0.00	0.00
	P/S	—	—	—	—	—	—	—	—	7.04	3.76
	P/B	—	—	—	—	—	—	—	—	0.17	0.09
	EV/Sales	—	—	—	—	—	—	—	—	7.59	4.76
	EV/FCF	—	—	—	—	—	—	—	—	(14.54)	(2.90)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	0	0	0	(1)	(2)	(4)
	Capex	—	—	—	—	—	—	—	—	0	(1)
	Free cash flow	—	—	—	—	0	0	0	(1)	(2)	(5)
Balance, $m
Balance, $m	Working capital	—	—	—	—	0	(1)	(1)	(2)	(1)	(14)
	Total debt	—	—	—	—	0	0	0	0	2	4
	Net debt	—	—	—	—	0	0	0	0	2	3
	Shareholders’ equity	—	—	—	—	0	0	0	(4)	143	127
Returns, %
Returns, %	ROA	—	—	—	—	0.00	(0.64)	(3.67)	2.13	(9.75)	(15.62)
	ROIC	—	—	—	—	0.00	(66.53)	0.00	0.00	(5.03)	(8.84)
	ROE	—	—	—	—	0.00	733.33	178.79	(20.48)	(14.83)	(20.03)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ENLV Enlivex Ltd.	$4.5M	0.0×	—	—	n/m	+35.94% (above 0%: growing)	0.00%	0.00%	Compare
NCNA NuCana PLC Sponsored ADR	$4.4M	— (loss-making)	—	—	n/m	+55.66% (above 0%: growing)	0.00%	0.00%	Compare
ADTX Aditxt, Inc.	$4.4M	— (loss-making)	—	+1,120.00% (above 0%: growing)	n/m	+60.82% (above 0%: growing)	23.77%	(35,753.28%)	Compare
AZTR Azitra, Inc.	$4.3M	1.0×	— (loss-making)	−93.38% (below 0%: shrinking)	n/m	−19.55% (below 0%: shrinking)	100.00%	0.00%	Compare
LIMN Liminatus Pharma Inc.	$4.3M	— (loss-making)	—	—	n/m	+89.00% (above 0%: growing)	—	0.00%	Compare
LNAI Lunai Bioworks Inc.	$4.2M	— (loss-making)	—	—	n/m	−1.65% (below 0%: shrinking)	100.00%	(6,877.49%)	Compare
JUNS Jupiter Neurosciences, Inc.	$4.1M	— (loss-making)	—	—	n/m	−177.06% (below 0%: shrinking)	87.19%	(11,334.30%)	Compare
OSRH OSR Health, Inc.	$4.1M	— (loss-making)	—	−72.20% (below 0%: shrinking)	n/m	−398.76% (below 0%: shrinking)	27.43%	(960.69%)
PMCB Nuvilex Inc.	$3.8M	— (loss-making)	—	−103.94% (below 0%: shrinking)	n/m	+60.84% (above 0%: growing)	100.00%	0.00%	Compare
Median of peers	$4.3M	—	—	−93.38%	—	+45.80%	87.19%	0.00%

All 614 Biotechnology stocks →

OSR Health, Inc. (OSRH) key facts

Concern: OSR Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, down 17.7% from fiscal 2024.
OSR Health, Inc. (OSRH) is a Biotechnology company in the Healthcare sector.
As of October 16, 2026, OSRH traded at $0.22, a market capitalization of $4.1 million.
Return on equity was −20.0% and debt-to-equity 0.04.
Its Altman Z-score is −0.59 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.